USING RECOMBINANT DNA TECHNOLOGY AND SOLID-PHASE DEOXYRIBONUCLEOTIDE SYNTHESIS, A UNIQUE HYBRID GENE CONSISTING OF A FRAGMENT OF DIPTHERIA TOXIN AND THE SEQUENCEENCODING APLHA-MELANOCYTE-STIMULATING HORMONE (MSH) HAS BEENCONSTRUCTED AND EXPRESSED IN E.

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$50,000.00
Award Year:
1986
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Award Id:
4778
Agency Tracking Number:
4778
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Ledgemont Research Center, 128 Spring Street, Lexington, MA, 02173
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
CORY A WATERS
PRINCIPAL INVESTIGATOR
(617) 862-7235
Business Contact:
() -
Research Institute:
n/a
Abstract
USING RECOMBINANT DNA TECHNOLOGY AND SOLID-PHASE DEOXYRIBONUCLEOTIDE SYNTHESIS, A UNIQUE HYBRID GENE CONSISTING OF A FRAGMENT OF DIPTHERIA TOXIN AND THE SEQUENCEENCODING APLHA-MELANOCYTE-STIMULATING HORMONE (MSH) HAS BEENCONSTRUCTED AND EXPRESSED IN E. COLI K12. PRELIMINARY STUDIES OF THE CYTOTOXIC PROPERTIES OF THIS NOVEL POLYPEP- TIDE (MSH-TOXIN) ON HUMAN MALIGNANT MELANOMA CELLS DEMONSTRATE THAT THE CHIMERIC MOLECULE POSSESSES CHARACTERISTICS INTRINSIC TO THE DIPTHERIA TOXIN (ABILITY TOADP-RIBOSYLATE EF-2 AND BLOCK PROTEIN SYNTHESIS) AND TO MSH (SPECIFICITY FOR MSH-RECEPTOR BEARING CELLS). THE HYBRID TOXIN-GENE PRODUCT HAS BEEN LICENSED BY SERAGEN, INC. THE LONG-RANGE OBJECTIVE OF THIS PROJECT IS TO EVALUATE THE POTENTIAL OF MSH-TOXIN AS A SPECIFIC CHEMOTHERAPEUTIC FOR THE TREATMENT OF HUMAN MALIGNANT MELANOMA. PHASE I OF THE PROJECT WILL (1) COMPLETE ASSESSMENT OF THE MOLECULE'S RECEPTOR-SPECIFC CYTOTOXICITY FOR HUMAN CELL LINES OR PATIENT MATERIAL BEARING MSH-RECEPTORS; () ANALYZE BY DUAL BEAM FLOW CYTOMETRY, DISTRIBUTION OF THE MSH RECEPTOR AS A FUNCTION OF CELL CYCLE ON IN VITRO AND IN VIVO PASSAGED MELANOMA CELLS; AND (3) ESTABLISH A HUMAN MELANOMA XENO- TRANSPLANT MODEL IN THE NUDE MOUSE TO CHARACTERIZE IN VIVO EFFICACY OF PRIMARY TUMOR TREATMENT WIH MSH-TOXIN. PHASE II OF THE PROJECT WILL FOCUS ON (1) EFFICACY OF MSH-TOXIN INA METASTATIC NUDE MOUSE MODEL; (2) DEVELOPMENT OF A BIOASSAYFOR MSH-TOXIN; AND (3) ANIMAL TOXICOLOGY AND INVESTIGATION OF MSH-TOXIN FATE AND DISTRIBUTION IN VIVO, INCLUDING EVALUATION OF IMPACT ON IMMUNE AND RETICULOENDOTHELIAL SYSTEMS.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government